Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives
The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews o...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Methods and Protocols |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2409-9279/6/3/45 |
| _version_ | 1827736165661278208 |
|---|---|
| author | Ana Salomé Pires Sveva Bollini Maria Filomena Botelho Ingrid Lang-Olip Peter Ponsaerts Carolina Balbi Anna Lange-Consiglio Mathilde Fénelon Slavko Mojsilović Ekaterine Berishvili Fausto Cremonesi Maria Gazouli Diana Bugarski Alexandra Gellhaus Halima Kerdjoudj Andreina Schoeberlein |
| author_facet | Ana Salomé Pires Sveva Bollini Maria Filomena Botelho Ingrid Lang-Olip Peter Ponsaerts Carolina Balbi Anna Lange-Consiglio Mathilde Fénelon Slavko Mojsilović Ekaterine Berishvili Fausto Cremonesi Maria Gazouli Diana Bugarski Alexandra Gellhaus Halima Kerdjoudj Andreina Schoeberlein |
| author_sort | Ana Salomé Pires |
| collection | DOAJ |
| description | The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation. |
| first_indexed | 2024-03-11T02:06:12Z |
| format | Article |
| id | doaj.art-4987941f2ee844d6ab0639396a9fbadb |
| institution | Directory Open Access Journal |
| issn | 2409-9279 |
| language | English |
| last_indexed | 2024-03-11T02:06:12Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Methods and Protocols |
| spelling | doaj.art-4987941f2ee844d6ab0639396a9fbadb2023-11-18T11:51:43ZengMDPI AGMethods and Protocols2409-92792023-04-01634510.3390/mps6030045Guidelines to Analyze Preclinical Studies Using Perinatal DerivativesAna Salomé Pires0Sveva Bollini1Maria Filomena Botelho2Ingrid Lang-Olip3Peter Ponsaerts4Carolina Balbi5Anna Lange-Consiglio6Mathilde Fénelon7Slavko Mojsilović8Ekaterine Berishvili9Fausto Cremonesi10Maria Gazouli11Diana Bugarski12Alexandra Gellhaus13Halima Kerdjoudj14Andreina Schoeberlein15Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment, Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, PortugalDepartment of Experimental Medicine (DIMES), University of Genova, 16132 Genova, ItalyCoimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment, Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, PortugalDivision of Cell Biology, Histology, Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, AustriaLaboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (Vaxinfectio), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, BelgiumLaboratory of Cellular and Molecular Cardiology, Istituto Cardiocentro Ticino, CH-6900 Lugano, SwitzerlandDepartment of Veterinary Medicine and Animal Science (DIVAS), Università degli Studi di Milano, Via Celoria, 10, 20133 Milano, ItalyINSERM U1026, University of Bordeaux, Tissue Bioengineering (BioTis), F-33076 Bordeaux, FranceGroup for Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, 11000 Belgrade, SerbiaLaboratory of Tissue Engineering and Organ Regeneration, University of Geneva, CH-1211 Geneva, SwitzerlandDepartment of Veterinary Medicine and Animal Science (DIVAS), Università degli Studi di Milano, Via Celoria, 10, 20133 Milano, ItalyDepartment of Basic Medical Sciences, Laboratory of Biology, Faculty of Medicine, School of Health Science, National and Kapodistrian University of Athens, 115 27 Athens, GreeceGroup for Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, 11000 Belgrade, SerbiaDepartment of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, D-45147 Essen, GermanyBiomatériaux et Inflammation en Site Osseux (BIOS), Université de Reims Champagne Ardenne, F-51097 Reims, FranceDepartment of Obstetrics and Feto-maternal Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, SwitzerlandThe last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.https://www.mdpi.com/2409-9279/6/3/45perinatal derivativespreclinical studiesanimal modelsdatabase searchconsensusprotocol |
| spellingShingle | Ana Salomé Pires Sveva Bollini Maria Filomena Botelho Ingrid Lang-Olip Peter Ponsaerts Carolina Balbi Anna Lange-Consiglio Mathilde Fénelon Slavko Mojsilović Ekaterine Berishvili Fausto Cremonesi Maria Gazouli Diana Bugarski Alexandra Gellhaus Halima Kerdjoudj Andreina Schoeberlein Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives Methods and Protocols perinatal derivatives preclinical studies animal models database search consensus protocol |
| title | Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives |
| title_full | Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives |
| title_fullStr | Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives |
| title_full_unstemmed | Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives |
| title_short | Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives |
| title_sort | guidelines to analyze preclinical studies using perinatal derivatives |
| topic | perinatal derivatives preclinical studies animal models database search consensus protocol |
| url | https://www.mdpi.com/2409-9279/6/3/45 |
| work_keys_str_mv | AT anasalomepires guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT svevabollini guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT mariafilomenabotelho guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT ingridlangolip guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT peterponsaerts guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT carolinabalbi guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT annalangeconsiglio guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT mathildefenelon guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT slavkomojsilovic guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT ekaterineberishvili guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT faustocremonesi guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT mariagazouli guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT dianabugarski guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT alexandragellhaus guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT halimakerdjoudj guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives AT andreinaschoeberlein guidelinestoanalyzepreclinicalstudiesusingperinatalderivatives |